Adjuvant therapy of biliary tract cancers

Area of Science:

• Oncology
• Gastroenterology
• Surgical Oncology

Background:

• Biliary tract cancers (BTCs) are rare, aggressive, and heterogeneous malignancies.
• Surgical resection is the only potentially curative option, but only 35% of patients present with resectable disease.
• Limited evidence previously existed for adjuvant treatments in BTCs.

Purpose of the Study:

• To review the latest evidence on adjuvant therapy for resectable biliary tract cancers.
• To establish current treatment standards based on recent findings.
• To highlight future research directions and prospects in adjuvant therapy for BTCs.

Main Methods:

• Review of recent clinical trials and retrospective studies.
• Analysis of data from the BILCAP trial.
• Synthesis of evidence regarding adjuvant capecitabine and other therapies.

Main Results:

• The BILCAP trial established adjuvant capecitabine as the standard of care for resectable BTCs.
• Historically, data for adjuvant treatments were limited to retrospective studies.
• Unanswered questions remain regarding the optimal role and benefit of adjuvant therapy.

Conclusions:

• Adjuvant capecitabine represents a significant advancement in BTC treatment.
• Further prospective studies and translational research are crucial for reproducible clinical benefit.
• Continued investigation is needed to refine adjuvant treatment strategies for resectable BTCs.